---
title: Teclistamab in relapsed or refractory AL amyloidosis, a multinational retrospective
  case series
date: '2023-12-14'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38096365/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20231215170556&v=2.18.0
source: Blood
description: Teclistamab shows promising results in R/R AL amyloidosis, with VGPR
  or better in 88% of patients and involved FLC < 10 mg/L in 76%. We observed a 35%
  rate of severe infections and no cardiac or kidney related ...
disable_comments: true
---
Teclistamab shows promising results in R/R AL amyloidosis, with VGPR or better in 88% of patients and involved FLC < 10 mg/L in 76%. We observed a 35% rate of severe infections and no cardiac or kidney related ...